PF-06263507

targets the cell-surface, tumor-associated antigen 5T4 and consists of a humanized IgG1 conjugated to the microtubule-disrupting agent monomethylauristatin-F by a non-cleavable maleimidocaproyl linker

Also Known As:

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Damle, Nitin K: 1 article (01/2021)
2.	Denis, Louis J: 1 article (01/2021)
3.	Gupta, Sandeep: 1 article (01/2021)
4.	Lin, Jun-Hsiang: 1 article (01/2021)
5.	Mistry, Mahesh: 1 article (01/2021)
6.	Rao, Niranjan S: 1 article (01/2021)
7.	Reddy, Sanjeeva P: 1 article (01/2021)
8.	Smith, Roger A: 1 article (01/2021)
9.	Usansky, Helen: 1 article (01/2021)
10.	Zammit, David J: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "In this first-in-human, dose-finding trial (NCT01891669), we evaluated safety, pharmacokinetics, and preliminary antitumor activity of PF-06263507 in pretreated patients with advanced solid tumors, unselected for 5T4 expression. " 01/01/2021 - "In head-to-head studies, superior activity of ASN004 was demonstrated against trastuzumab-DM1, in a low-5T4/high-HER2 expressing gastric tumor model, and 10-fold greater potency was found for ASN004 against the 5T4-targeted ADC PF-06263507 in a lung tumor model. " 01/01/2017 - "First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors." 01/01/2017 - "Background The antibody-drug conjugate PF-06263507 targets the cell-surface, tumor-associated antigen 5T4 and consists of a humanized IgG1 conjugated to the microtubule-disrupting agent monomethylauristatin-F by a non-cleavable maleimidocaproyl linker. "
2.	Photophobia (Light Sensitivity) 01/01/2017 - "Results Twenty-six patients received PF-06263507 at 0.05 to 6.5 mg/kg. The first DLT, grade 3 photophobia, occurred at 4.34 mg/kg and two additional DLTs, grade 2 keratitis and grade 1 limbal stem cell deficiency (> 2-week dosing delay), at 6.5 mg/kg. The most common adverse events (AEs) were fatigue (38.5%), photophobia (26.9%), and decreased appetite, dry eye, nausea, and thrombocytopenia (23.1% each). "
3.	Dry Eye Syndromes (Dry Eye Syndrome) 01/01/2017 - "Results Twenty-six patients received PF-06263507 at 0.05 to 6.5 mg/kg. The first DLT, grade 3 photophobia, occurred at 4.34 mg/kg and two additional DLTs, grade 2 keratitis and grade 1 limbal stem cell deficiency (> 2-week dosing delay), at 6.5 mg/kg. The most common adverse events (AEs) were fatigue (38.5%), photophobia (26.9%), and decreased appetite, dry eye, nausea, and thrombocytopenia (23.1% each). "
4.	Thrombocytopenia (Thrombopenia) 01/01/2017 - "Results Twenty-six patients received PF-06263507 at 0.05 to 6.5 mg/kg. The first DLT, grade 3 photophobia, occurred at 4.34 mg/kg and two additional DLTs, grade 2 keratitis and grade 1 limbal stem cell deficiency (> 2-week dosing delay), at 6.5 mg/kg. The most common adverse events (AEs) were fatigue (38.5%), photophobia (26.9%), and decreased appetite, dry eye, nausea, and thrombocytopenia (23.1% each). "
5.	Nausea 01/01/2017 - "Results Twenty-six patients received PF-06263507 at 0.05 to 6.5 mg/kg. The first DLT, grade 3 photophobia, occurred at 4.34 mg/kg and two additional DLTs, grade 2 keratitis and grade 1 limbal stem cell deficiency (> 2-week dosing delay), at 6.5 mg/kg. The most common adverse events (AEs) were fatigue (38.5%), photophobia (26.9%), and decreased appetite, dry eye, nausea, and thrombocytopenia (23.1% each). "

Related Drugs and Biologics

1.	PF-06263507
2.	Ado-Trastuzumab Emtansine
3.	Immunoconjugates (Immunoconjugate)
4.	Immunoglobulin G (IgG)
5.	Antigens
6.	monomethylauristatin F